• Introduction
• General Considerations for oncology efficacy and safety clinical evaluation
• Early-phase clinical development of CAR T cells for patients with hematologic malignancies
• Biomarker and tissue agnostic drug development
• Patient-Reported Outcomes (PROs)
• Regulatory considerations for use of minimal residual disease (MRD) for treatment hematologic malignancies
• Considerations for the development of drugs and biological products in rare cancers and pediatrics
• Subgroup analysis  in oncology controlled trials
• Gene therapy in hematological diseases
• Questions and general discussion

Work Shop Link Remotely : Click Here